Christina Yap
@christinayap.bsky.social
Professor of Clinical Trials Biostatistics, The Institute of Cancer Research, UK
Reposted by Christina Yap
Congratulations to Cross-Sector Experience Award recipient @christinayap.bsky.social 🎉
Through this award Prof Yap will work with AstraZeneca & Bayer to improve the design of early-phase trials, ensuring they are more effective & impactful for patients.
👉 bit.ly/45a0VWy
#CrossSector @icr.ac.uk
Through this award Prof Yap will work with AstraZeneca & Bayer to improve the design of early-phase trials, ensuring they are more effective & impactful for patients.
👉 bit.ly/45a0VWy
#CrossSector @icr.ac.uk
August 15, 2025 at 12:57 PM
Congratulations to Cross-Sector Experience Award recipient @christinayap.bsky.social 🎉
Through this award Prof Yap will work with AstraZeneca & Bayer to improve the design of early-phase trials, ensuring they are more effective & impactful for patients.
👉 bit.ly/45a0VWy
#CrossSector @icr.ac.uk
Through this award Prof Yap will work with AstraZeneca & Bayer to improve the design of early-phase trials, ensuring they are more effective & impactful for patients.
👉 bit.ly/45a0VWy
#CrossSector @icr.ac.uk
A real pleasure running this workshop with you and Devin Peipert - thank you so much! Had such an engaging and interactive group too!
Presenting a #patientreportedoutcomes workshop at Society for Clinical Trials 46th Annual Meeting! #SCT2025 #clinicaltrials #PROs @christinayap.bsky.social
May 19, 2025 at 5:41 AM
A real pleasure running this workshop with you and Devin Peipert - thank you so much! Had such an engaging and interactive group too!
Thank you for the kind invitation to share insights on the value of PROs in phase I dose-finding trials. A fantastic conference in the beautiful city of Barcelona - I’ve learnt so much too! Such a privilege to be part of it!
🩺 Phase 1 oncology trials focus on safety—but PROs can add real value. They complement clinician-reported dose-limiting toxicity (DLTs), offering a fuller view of treatment impact. Interest is growing across patients, researchers & regulators.
- @christinayap.bsky.social @eortc.org #QoLConf25
- @christinayap.bsky.social @eortc.org #QoLConf25
May 13, 2025 at 9:20 PM
Thank you for the kind invitation to share insights on the value of PROs in phase I dose-finding trials. A fantastic conference in the beautiful city of Barcelona - I’ve learnt so much too! Such a privilege to be part of it!
Passionate about cancer trials, patient-reported outcomes (PROs) & innovative methods?
Join the Early Phase and Adaptive Trials Group at @icr-ctsu.bsky.social @icrlondon.bsky.social for an exciting undergraduate summer scholarship in early phase trials & PROs!
Deadline: 26/01/25
shorturl.at/1h565
Join the Early Phase and Adaptive Trials Group at @icr-ctsu.bsky.social @icrlondon.bsky.social for an exciting undergraduate summer scholarship in early phase trials & PROs!
Deadline: 26/01/25
shorturl.at/1h565
Undergraduate Summer Scholarship Scheme - The Institute of Cancer Research, London
Our paid undergraduate summer scholarships offer undergraduate students a chance to gain hands-on cancer research experience.
www.icr.ac.uk
January 18, 2025 at 10:16 PM
Passionate about cancer trials, patient-reported outcomes (PROs) & innovative methods?
Join the Early Phase and Adaptive Trials Group at @icr-ctsu.bsky.social @icrlondon.bsky.social for an exciting undergraduate summer scholarship in early phase trials & PROs!
Deadline: 26/01/25
shorturl.at/1h565
Join the Early Phase and Adaptive Trials Group at @icr-ctsu.bsky.social @icrlondon.bsky.social for an exciting undergraduate summer scholarship in early phase trials & PROs!
Deadline: 26/01/25
shorturl.at/1h565